USA - NASDAQ:UPXI - US39959A2050 - Common Stock
The current stock price of UPXI is 3.305 USD. In the past month the price decreased by -47.95%. In the past year, price decreased by -35.32%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| EL | ESTEE LAUDER COMPANIES-CL A | 52.23 | 31.62B | ||
| KVUE | KENVUE INC | 15.78 | 32.39B | ||
| ELF | ELF BEAUTY INC | 23.86 | 4.18B | ||
| BRBR | BELLRING BRANDS INC | 13.49 | 3.69B | ||
| COTY | COTY INC-CL A | 19.74 | 3.28B | ||
| IPAR | INTERPARFUMS INC | 16.68 | 2.81B | ||
| EPC | EDGEWELL PERSONAL CARE CO | 7.26 | 870.20M | ||
| OLPX | OLAPLEX HOLDINGS INC | 18.33 | 733.79M | ||
| NUS | NU SKIN ENTERPRISES INC - A | 6.61 | 451.44M | ||
| USNA | USANA HEALTH SCIENCES INC | 9.76 | 349.51M | ||
| HNST | HONEST CO INC/THE | 53.3 | 296.53M | ||
| NATR | NATURES SUNSHINE PRODS INC | 19.06 | 316.11M |
Upexi, Inc. engages in the development, manufacturing, and distribution of consumer products through direct-to-consumer network, wholesale partnerships, and major third-party platforms like Amazon. The company is headquartered in Tampa, Florida and currently employs 59 full-time employees. The company went IPO on 2021-06-24. The firm is a brand owner specializing in the development, manufacturing and distribution of consumer products with diversification into the cryptocurrency space. The Company’s brands include Lucky Tail, PRAX, and Cure Mushrooms. Lucky Tail is a pet care product brand that provides products from grooming tools to nutritional products. Cure Mushrooms is a full line of medicinal mushroom products, designed by effect for consumers, which offers mushroom extracts in tinctures and gummies. PRAX is a full line of medicinal mushroom products, designed by effect for consumers, which are cultivated, extracted, and produced in the United States. Its products are distributed in the United States of America and internationally through multiple entities and managed through locations in Florida.
UPEXI INC
3030 Rocky Point Drive, Suite 420
Tampa FLORIDA US
Employees: 59
Phone: 17013535425
Upexi, Inc. engages in the development, manufacturing, and distribution of consumer products through direct-to-consumer network, wholesale partnerships, and major third-party platforms like Amazon. The company is headquartered in Tampa, Florida and currently employs 59 full-time employees. The company went IPO on 2021-06-24. The firm is a brand owner specializing in the development, manufacturing and distribution of consumer products with diversification into the cryptocurrency space. The Company’s brands include Lucky Tail, PRAX, and Cure Mushrooms. Lucky Tail is a pet care product brand that provides products from grooming tools to nutritional products. Cure Mushrooms is a full line of medicinal mushroom products, designed by effect for consumers, which offers mushroom extracts in tinctures and gummies. PRAX is a full line of medicinal mushroom products, designed by effect for consumers, which are cultivated, extracted, and produced in the United States. Its products are distributed in the United States of America and internationally through multiple entities and managed through locations in Florida.
The current stock price of UPXI is 3.305 USD. The price decreased by -0.15% in the last trading session.
UPXI does not pay a dividend.
UPXI has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
UPEXI INC (UPXI) has a market capitalization of 194.63M USD. This makes UPXI a Micro Cap stock.
You can find the ownership structure of UPEXI INC (UPXI) on the Ownership tab.
ChartMill assigns a fundamental rating of 2 / 10 to UPXI. Both the profitability and financial health of UPXI have multiple concerns.
Over the last trailing twelve months UPXI reported a non-GAAP Earnings per Share(EPS) of -5.91. The EPS increased by 69.38% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -11.05% | ||
| ROE | -15.19% | ||
| Debt/Equity | 0.22 |
8 analysts have analysed UPXI and the average price target is 15.81 USD. This implies a price increase of 378.37% is expected in the next year compared to the current price of 3.305.
For the next year, analysts expect an EPS growth of 103.26% and a revenue growth 147.95% for UPXI